Aduro Biotech, Inc. (ADRO) EVP Sells $77,760.00 in Stock

Aduro Biotech, Inc. (NASDAQ:ADRO) EVP Dirk G. Brockstedt sold 8,000 shares of Aduro Biotech stock in a transaction that occurred on Thursday, May 11th. The shares were sold at an average price of $9.72, for a total transaction of $77,760.00. Following the completion of the sale, the executive vice president now owns 57,300 shares of the company’s stock, valued at $556,956. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Dirk G. Brockstedt also recently made the following trade(s):

  • On Wednesday, May 17th, Dirk G. Brockstedt sold 1,011 shares of Aduro Biotech stock. The shares were sold at an average price of $9.65, for a total transaction of $9,756.15.

Aduro Biotech, Inc. (NASDAQ ADRO) traded up 0.48% during mid-day trading on Friday, hitting $10.55. 713,044 shares of the company’s stock were exchanged. Aduro Biotech, Inc. has a 12 month low of $8.75 and a 12 month high of $16.43. The stock’s 50 day moving average price is $10.11 and its 200-day moving average price is $10.72. The stock’s market cap is $737.58 million.

Aduro Biotech (NASDAQ:ADRO) last posted its quarterly earnings data on Tuesday, May 2nd. The biotechnology company reported ($0.32) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.39) by $0.07. The firm had revenue of $3.77 million for the quarter, compared to analysts’ expectations of $3.74 million. Aduro Biotech had a negative net margin of 166.85% and a negative return on equity of 35.35%. Equities analysts expect that Aduro Biotech, Inc. will post ($1.39) EPS for the current fiscal year.

Insider Buying and Selling by Quarter for Aduro Biotech (NASDAQ:ADRO)

ILLEGAL ACTIVITY WARNING: This piece was first reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be read at https://www.chaffeybreeze.com/2017/06/17/dirk-g-brockstedt-sells-8000-shares-of-aduro-biotech-inc-adro-stock-updated-updated-updated.html.

Several research analysts have commented on ADRO shares. Canaccord Genuity set a $30.00 price objective on shares of Aduro Biotech and gave the company a “buy” rating in a research report on Thursday, March 2nd. Roth Capital restated a “buy” rating and set a $17.00 price objective on shares of Aduro Biotech in a research report on Tuesday, March 7th. FBR & Co restated a “buy” rating and set a $23.00 price objective on shares of Aduro Biotech in a research report on Tuesday, March 7th. Rodman & Renshaw started coverage on shares of Aduro Biotech in a research report on Monday, May 1st. They set a “buy” rating and a $18.00 price objective for the company. Finally, HC Wainwright started coverage on shares of Aduro Biotech in a research report on Monday, May 1st. They set a “buy” rating and a $18.00 price objective for the company. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $20.00.

A number of institutional investors have recently modified their holdings of the company. Vident Investment Advisory LLC boosted its position in shares of Aduro Biotech by 13.6% in the fourth quarter. Vident Investment Advisory LLC now owns 65,874 shares of the biotechnology company’s stock worth $751,000 after buying an additional 7,884 shares during the last quarter. Norges Bank acquired a new position in shares of Aduro Biotech during the fourth quarter worth approximately $3,266,000. Clough Capital Partners L P boosted its position in shares of Aduro Biotech by 11.7% in the fourth quarter. Clough Capital Partners L P now owns 326,400 shares of the biotechnology company’s stock worth $3,721,000 after buying an additional 34,200 shares during the last quarter. Tudor Investment Corp Et Al acquired a new position in shares of Aduro Biotech during the fourth quarter worth approximately $131,000. Finally, Renaissance Technologies LLC acquired a new position in shares of Aduro Biotech during the fourth quarter worth approximately $241,000. Institutional investors own 35.68% of the company’s stock.

Aduro Biotech Company Profile

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply